Swahili
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia

Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
Kiungo kimehifadhiwa kwenye clipboard
Hali
Wadhamini
Federal Neuro-Psychiatric Hospital, Yaba

Maneno muhimu

Kikemikali

Sorghum bicolor is a naturally growing plant which has been of health benefit to the people of West Africa who traditionally prepare its leaf for various nutritional and health reasons.The food and nutritional fact analysis showed that Jobelyn is rich in Carbohydrates, Protein, Dietary Fiber, Iron, Natural Vitamins like B12 and Vitamin C. It also contains Selenium, Omega 3,6 and 9 and other essential elements and fatty acids. Although the determinants of mental health are complex, the emerging and compelling evidence for nutrition as a crucial factor in the high prevalence and incidence of mental disorders suggests that diet is as important to psychiatry as it is to cardiology, endocrinology, and gastroenterology. Evidence is steadily growing for the relation between dietary quality (and potential nutritional deficiencies) and mental health, and for the select use of nutrient-based supplements to address deficiencies, or as monotherapies or augmentation therapies. There is currently strong advocacy for the recognition of diet and nutrition as central determinants of both physical and mental health.Its anti-inflammatory and haematocrit boosting properties have been well documented though the precise mechanism of action is still largely unknown. Its use has recently been extended to the field of mental health where findings in animal study suggest it could be of help in relieve of psychosis. The need for this study is therefore aimed at investigating the effect of this drug in patients with schizophrenia which is the prototypical psychotic disorder.

Maelezo

Schizophrenia is a major psychiatric disorder with a chronic and debilitating course. It is the archetypal psychotic disorder with a prevalence of about 1% worldwide. The treatment of this psychotic disorder has evolved over the years after the discovery of Chlorpromazine. Despite the availability of several treatment options in practice, research into the possibility of creating a drug breakthrough continues.

Sorghum bicolor, a naturally growing plant rich in several phytochemical including proanthocyanidins, anthocyanidins, apigenin, proapigeninidin, apigeninidin, luteolin, naringenins, flavonoids, and polyphenols (Omogbiya et al 2012) and prepared as a capsule called Jobelyn. This plant has been found to be of health benefit to the people of West Africa who traditionally prepare its leaf for various nutritional and health reasons. The anti-inflammatory and haematocrit boosting properties have been well documented and utilized though the precise mechanism of action is still not entirely known (Benson et al. 2013). Its usefulness in neuropsychiatric conditions has recently been explored albeit through animal studies.

In animals, Jobelyn has been suggested to have anti-amnestic property which has been suggested to be related to its antioxidant activity (Umukoro et al. 2013a). Other studies also suggested that Jobelyn has an anti-aggressive effect (Umukoro et al. 2012) and antidepressant like property probably related to its stimulation of serotonergic pathways (Umukoro et al. 2013b). Jobelyn has also been suggested to exhibit anti-psychotic-like activity with the benefit of lacking extra-pyramidal side effect risks and therefore being postulated to be of possible benefit in the symptomatic relief of psychosis (Omogbiya et al. 2012).

There is however limited information in terms of the suggested neuropsychiatric conditions especially in humans despite the recognized safety profile consequent upon its use as haematocrit boosting agent. This study therefore aims at exploring the usefulness of Jobelyn in the treatment of patients with Schizophrenia as an adjunct to standard treatment.

Tarehe

Imethibitishwa Mwisho: 01/31/2017
Iliyowasilishwa Kwanza: 09/10/2014
Uandikishaji uliokadiriwa Uliwasilishwa: 09/10/2014
Iliyotumwa Kwanza: 09/14/2014
Sasisho la Mwisho Liliwasilishwa: 02/13/2017
Sasisho la Mwisho Lilichapishwa: 02/15/2017
Tarehe halisi ya kuanza kwa masomo: 05/31/2017
Tarehe ya Kukamilisha Msingi iliyokadiriwa: 11/30/2017
Tarehe ya Kukamilisha Utafiti: 11/30/2017

Hali au ugonjwa

Schizophrenia and Disorders With Psychotic Features

Uingiliaji / matibabu

Dietary Supplement: Jobelyn + Haloperidol

Drug: Haloperidol + Placebo

Awamu

Awamu 1/Awamu 2

Vikundi vya Arm

MkonoUingiliaji / matibabu
Experimental: Jobelyn + Haloperidol
Combination of the conventional drugs and Jobelyn
Dietary Supplement: Jobelyn + Haloperidol
Jobelyn is a dietary supplement made from Sorghum bicolor
Active Comparator: Haloperidol + Placebo
Combination of the conventional drug + Placebo
Drug: Haloperidol + Placebo
Conventional drug normally used for psychotic problems

Vigezo vya Kustahiki

Jinsia Inastahiki KujifunzaAll
Hupokea Wajitolea wa AfyaNdio
Vigezo

Inclusion Criteria:

Participants will be adults with current diagnosis of schizophrenia (meeting the ICD-10 criteria).

- Adults who are above 18 years of age and gave informed consent

- Currently meet the ICD-10 diagnosis of Schizophrenia and confirmed with MINI- PLUS

- Antipsychotic naive before recruitment into study or defaulted from treatment for at least 6 months 'prior to contact with study

- Not on Jobelyn or Megafit currently or in the past 6months prior to contact with study

Exclusion Criteria:

- Having another current ICD-l0 diagnosis or a seizure disorder

- Serious or chronic physical illness

- Known severe drug allergies or hypersensitivity to Jobelyn, Megafit or Haloperidol

Matokeo

Hatua za Matokeo ya Msingi

1. The primary outcome will be the changes in psychotic symptoms [8 Weeks]

This will be rated using the Brief Psychiatric Rating Scale (BPRS).

Hatua za Matokeo ya Sekondari

1. Patient's general health and social functioning [8 Weeks]

To be assessed using the Clinical Global Impression Scale.

Hatua Nyingine za Matokeo

1. Side effects [8 Weeks]

This will be measured using a side-effect scale designed for the study

Jiunge na ukurasa
wetu wa facebook

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi

  • Inafanya kazi katika lugha 55
  • Uponyaji wa mitishamba unaungwa mkono na sayansi
  • Kutambua mimea kwa picha
  • Ramani ya GPS inayoshirikiana
  • Soma machapisho ya kisayansi yanayohusiana na utafutaji wako
  • Tafuta mimea ya dawa na athari zao
  • Panga maslahi yako na fanya tarehe ya utafiti wa habari, majaribio ya kliniki na ruhusu

Andika dalili au ugonjwa na usome juu ya mimea ambayo inaweza kusaidia, chapa mimea na uone magonjwa na dalili ambazo hutumiwa dhidi yake.
* Habari zote zinategemea utafiti wa kisayansi uliochapishwa

Google Play badgeApp Store badge